InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company’s technologies incorporate intellectual property licensed under an exclusive around the world license from Boston Children’s Hospital (BCH) and the Massachusetts Institute of Technology (MIT), and intellectual property that has been developed internally, including in collaboration with its advisors and partners. The Company intends to leverage its platform technology to develop the Neuro-Spinal Scaffold, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury (SCI). The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
